The fight against global infectious diseases is made significantly more achievable through collaboration. Takeda is forging partnerships and collaborating across R&D, clinical science, operations and commercial functions to achieve its mission of making important vaccines available to those who need them.
Collaboration with Frazier Healthcare Partners to launch HilleVax, Inc., a biopharmaceutical company to advance the development and commercialization of norovirus vaccine candidate HIL-214 (formerly TAK-214).1
Completed multiple subsidy programs for BLB-750 for Japanese pandemic influenza preparedness.
Partnership to rapidly and sustainably supply COVID-19 vaccines in Japan.
Manufacturing and commercializing Novavax’ COVID-19 vaccine (Nuvaxovid) at Hikari facility in Japan during the pandemic and beyond.2
Importing and distributing Moderna’s COVID-19 vaccine (Spikevax) to Japan during the pandemic.3
Contract to develop TAK-426, a Zika vaccine candidate, for the U.S. with the option to use data generated for filing also in affected regions around the world.4